$XERI
XERIANT, INC. Stock $xeri

$xeri Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000147793222000865 Filed on February 15, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$825.3K	$1.167M	$1.800M
YoY Change	481.61%	9.61%	4903.05%
% of Gross Profit
Research & Development	$7.587K	$2.860M	$2.341M
YoY Change
% of Gross Profit
Depreciation & Amortization	$250.00	$80.00
YoY Change
% of Gross Profit
Operating Expenses	$1.071M	$4.260M	$4.252M
YoY Change	368.6%	280.11%	4468.83%
Operating Profit	-$1.071M	-$4.260M	-$4.252M
YoY Change	368.6%	280.11%	4468.83%
Interest Expense	$134.9K	$1.625K	$2.389K
YoY Change	4970.54%	42.67%	119.78%
% of Operating Profit
Other Income/Expense, Net	-$1.734M	-$1.267M	-$195.7K
YoY Change	1537.24%	1643.76%	-16.37%
Pretax Income	-$2.805M	-$5.526M	-$4.448M
YoY Change	738.61%	363.11%	1259.93%
Income Tax
% Of Pretax Income
Net Earnings	-$2.805M	-$5.526M	-$4.448M
YoY Change	738.6%	363.11%	1259.92%
Net Earnings / Revenue
Basic Earnings Per Share			-$0.02
Diluted Earnings Per Share	-$7.709K	-$9.891K	-$14.50K
COMMON SHARES
Basic Shares Outstanding	364.3M shares	322.6M shares	225.5M shares
Diluted Shares Outstanding			225.5M shares

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.694M	$2.111M	$281.9K
YoY Change	12.41%	10646.18%	570.11%
Cash & Equivalents	$1.693M	$2.111M	$281.8K
Short-Term Investments
Other Short-Term Assets	$14.34K	$15.37K	$48.64K
YoY Change	-81.22%	12.85%	265.17%
Inventory
Prepaid Expenses	$1.790K	$2.823K
Receivables
Other Receivables
Total Short-Term Assets	$1.708M	$2.126M	$330.5K
YoY Change	7.89%	6291.82%	496.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.66K	$4.907K	$159.4K
YoY Change	-89.0%	-97.39%	-19.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$158.6K	$154.2K	$159.4K
YoY Change	-11.28%	-18.02%	-19.19%
TOTAL ASSETS
Total Short-Term Assets	$1.708M	$2.126M	$330.5K
Total Long-Term Assets	$158.6K	$154.2K	$159.4K
Total Assets	$1.866M	$2.280M	$489.9K
YoY Change	5.95%	929.96%	93.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$33.96K	$23.74K	$26.18K
YoY Change	81.22%	-20.87%	-2.35%
Accrued Expenses	$30.00K	$30.00K	$27.50K
YoY Change	-55.99%	-49.34%	-45.35%
Deferred Revenue
YoY Change
Short-Term Debt	$2.320M	$721.1K	$139.7K
YoY Change	2153.93%	3035.04%	380.79%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.418M	$820.5K	$237.5K
YoY Change	1174.03%	652.77%	123.69%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$117.6K	$117.6K	$129.7K
YoY Change	-22.83%	-28.0%	-25.4%
Total Long-Term Liabilities	$117.6K	$117.6K	$129.7K
YoY Change	-22.83%	-28.0%	-25.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.418M	$820.5K	$237.5K
Total Long-Term Liabilities	$117.6K	$117.6K	$129.7K
Total Liabilities	$2.536M	$938.1K	$367.2K
YoY Change	641.11%	244.5%	31.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.83M	-$10.03M
YoY Change
Common Stock	$3.633K	$3.577K	$3.221K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$669.6K	$1.342M	$122.7K
YoY Change
Total Liabilities & Shareholders Equity	$1.866M	$2.280M	$489.9K
YoY Change	5.95%	929.96%	93.92%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q3
OPERATING ACTIVITIES
Net Income	-$2.805M	-$5.526M	-$4.448M
YoY Change	738.6%	363.11%	1259.92%
Depreciation, Depletion And Amortization	$250.00	$80.00
YoY Change
Cash From Operating Activities	-$402.1K	-$3.285M	-$2.728M
YoY Change	93.65%	3701.5%	3482.77%
INVESTING ACTIVITIES
Capital Expenditures	-$15.00K	-$4.990K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$15.00K	-$4.990K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.669M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	5.119M	$2.047M
YoY Change	-100.0%	7898.36%	2481.45%
NET CHANGE
Cash From Operating Activities	-402.1K	-3.285M	-$2.728M
Cash From Investing Activities	-15.00K	-4.990K	$0.00
Cash From Financing Activities	0.000	5.119M	$2.047M
Net Change In Cash	-417.1K	1.829M	-$680.7K
YoY Change	-128.05%	-8256.56%	-21605.59%
FREE CASH FLOW
Cash From Operating Activities	-$402.1K	-$3.285M	-$2.728M
Capital Expenditures	-$15.00K	-$4.990K	$0.00
Free Cash Flow	-$387.1K	-$3.280M	-$2.728M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	364278386	shares
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2110549	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	962540	USD
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	12546	USD
CY2021Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	12546	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2823	USD
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1234	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2125918	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	976320	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4907	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149310	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169209	USD
CY2021Q4	us-gaap	Assets Assets	2280135	USD
CY2021Q2	us-gaap	Assets Assets	1145529	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23744	USD
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	73224	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25000	USD
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	721055	USD
CY2021Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	158196	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45720	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	42643	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	820519	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	299063	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117585	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	141160	USD
CY2021Q4	us-gaap	Liabilities Liabilities	938104	USD
CY2021Q2	us-gaap	Liabilities Liabilities	440223	USD
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	358202770	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	292815960	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3577	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	2925	USD
CY2021Q4	xeri	Common Stock To Be Issued CommonStockToBeIssued	347900	shares
CY2021Q2	xeri	Common Stock To Be Issued CommonStockToBeIssued	51090	shares
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14451855	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4138194	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10029764	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3270235	USD
CY2021Q4	xeri	Controlling Interest ControllingInterest	4773586	USD
CY2021Q2	xeri	Controlling Interest ControllingInterest	921992	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-3431555	USD
CY2021Q2	us-gaap	Minority Interest MinorityInterest	-216686	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1342031	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	705306	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2280135	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1145529	USD
CY2021Q4	us-gaap	Marketing Expense MarketingExpense	46623	USD
CY2020Q4	us-gaap	Marketing Expense MarketingExpense	1027109	USD
	us-gaap	Marketing Expense MarketingExpense	645218	USD
	us-gaap	Marketing Expense MarketingExpense	1027109	USD
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1120250	USD
CY2020Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37469	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2321252	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	73439	USD
CY2021Q4	us-gaap	Professional Fees ProfessionalFees	102484	USD
CY2020Q4	us-gaap	Professional Fees ProfessionalFees	14637	USD
	us-gaap	Professional Fees ProfessionalFees	132025	USD
	us-gaap	Professional Fees ProfessionalFees	35237	USD
CY2021Q4	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	130925	USD
CY2020Q4	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	41500	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	213425	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7166000	USD
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2021Q4	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	-1264931	USD
CY2020Q4	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	-66449	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	78000	USD
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2859644	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5200219	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	4259926	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	1120715	USD
	us-gaap	Operating Expenses OperatingExpenses	8512139	USD
	us-gaap	Operating Expenses OperatingExpenses	1213785	USD
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4259926	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1120715	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8512139	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1213785	USD
	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	-1413959	USD
	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	-112410	USD
CY2021Q4	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	USD
CY2020Q4	us-gaap	Adjustment For Amortization AdjustmentForAmortization	-3044	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	-5000	USD
CY2021Q4	us-gaap	Legal Fees LegalFees	0	USD
	us-gaap	Legal Fees LegalFees	43750	USD
	us-gaap	Legal Fees LegalFees	0	USD
CY2021Q4	us-gaap	Interest Expense InterestExpense	1625	USD
CY2020Q4	us-gaap	Interest Expense InterestExpense	1139	USD
	us-gaap	Interest Expense InterestExpense	4014	USD
	us-gaap	Interest Expense InterestExpense	2196	USD
CY2021Q4	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
CY2020Q4	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	46	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
CY2021Q4	xeri	Gain On Forgiveness Of Accounts Payable GainOnForgivenessOfAccountsPayable	0	USD
CY2020Q4	xeri	Gain On Forgiveness Of Accounts Payable GainOnForgivenessOfAccountsPayable	-1956	USD
	xeri	Gain On Forgiveness Of Accounts Payable GainOnForgivenessOfAccountsPayable	0	USD
	xeri	Gain On Forgiveness Of Accounts Payable GainOnForgivenessOfAccountsPayable	0	USD
CY2021Q4	xeri	Loss On Settlement Of Debt LossOnSettlementOfDebt	-4	USD
CY2020Q4	xeri	Loss On Settlement Of Debt LossOnSettlementOfDebt	0	USD
	xeri	Loss On Settlement Of Debt LossOnSettlementOfDebt	-536	USD
	xeri	Loss On Settlement Of Debt LossOnSettlementOfDebt	-186954	USD
CY2021Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1266560	USD
CY2020Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-72634	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1462259	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-306636	USD
CY2021Q4	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2037053	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3214869	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	0	USD
CY2021Q4	xeri	Common Stockholders CommonStockholders	-3489430	USD
	xeri	Common Stockholders CommonStockholders	-6759529	USD
	xeri	Common Stockholders CommonStockholders	0	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-5526486	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-1193349	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9974398	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1520421	USD
CY2021Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2021Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	352796331	shares
CY2020Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	234451953	shares
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	143300	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1148009	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19257	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	962540	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4447915	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	122688	USD
CY2021Q4	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	USD
CY2021Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	116104	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	328392903	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	176685459	shares
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	827221	USD
CY2021Q4	xeri	Fair Value Of Warrants Associated With Convertible Debt FairValueOfWarrantsAssociatedWithConvertibleDebt	2777081	USD
CY2021Q4	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	2365419	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1342031	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9974398	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1520421	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	USD
	xeri	Cash From Exercise Of Warrants CashFromExerciseOfWarrants	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4958950	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	705306	USD
CY2021Q3	xeri	Issuance Of Common Stock Committed In Prior Period Amount IssuanceOfCommonStockCommittedInPriorPeriodAmount	0	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1668500	USD
CY2021Q3	xeri	Shares Issued As Equity Kicker Amount SharesIssuedAsEquityKickerAmount	43753	USD
CY2021Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	128550	USD
CY2021Q3	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	541100	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	1060324	USD
CY2021Q3	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	250000	USD
CY2021Q4	xeri	Issuance Of Common Stock Committed In Prior Period Amount IssuanceOfCommonStockCommittedInPriorPeriodAmount	0	USD
CY2021Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	410000	USD
CY2021Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1887545	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1027109	USD
	xeri	Stock Issued For Services StockIssuedForServices	657204	shares
	us-gaap	Legal Fees LegalFees	43750	USD
	us-gaap	Legal Fees LegalFees	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	186954	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1413959	USD
	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	0	USD
	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	5000	USD
	xeri	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	19899	USD
	xeri	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	247	USD
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-20498	USD
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	0	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-1589	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	271	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-49475	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	25873	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	5000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	0	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5520	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6013001	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-162557	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4990	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2078500	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51000	USD
	xeri	Cash From Exercise Of Warrants CashFromExerciseOfWarrants	128550	USD
	xeri	Beneficial Conversion Feature Arising From Convertible Notes Payable BeneficialConversionFeatureArisingFromConvertibleNotesPayable	49505	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	92300	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38893	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2110549	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19636	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	437246	USD
	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	129859	USD
	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	2777081	USD
	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	42795	USD
	xeri	Beneficial Conversion Feature Arising From Convertible Notes Payable BeneficialConversionFeatureArisingFromConvertibleNotesPayable	2615419	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;font-family:times new roman;margin:0px">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates.</p>
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	2365419	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5200219	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	164713	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	0	USD
	xeri	Income Tax Positions Percentage Description IncomeTaxPositionsPercentageDescription	greater than 50%
	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	1855883	USD
	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.10	pure
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	4659	USD
CY2021Q4	xeri	Office Lease OfficeLease	220448	USD
CY2021Q4	xeri	Less Accumulated Amortization LessAccumulatedAmortization	-71138	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149310	USD
CY2021Q4	xeri	Office Leas OfficeLeas	163305	USD
CY2021Q4	xeri	Less Current Portion LessCurrentPortion	-45720	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117585	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	29607	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	60392	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	62201	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	37112	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	189312	USD
CY2021Q4	xeri	Present Value Discount PresentValueDiscount	-26007	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	163305	USD
CY2021Q4	xeri	Conversion Of Convertible Notes Payable ConversionOfConvertibleNotesPayable	721055	USD
CY2021Q2	xeri	Conversion Of Convertible Notes Payable ConversionOfConvertibleNotesPayable	158196	USD
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	6050000	USD
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	167550	USD
CY2021Q4	xeri	Less Unamortized Discount LessUnamortizedDiscount	-5328945	USD
CY2021Q2	xeri	Less Unamortized Discount LessUnamortizedDiscount	-9354	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	721055	USD
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	158196	USD
	xeri	Warrants Issued WarrantsIssued	50968828	shares
	xeri	Debt Instrument Convertible Beneficial Conversion Feature For Future DebtInstrumentConvertibleBeneficialConversionFeatureForFuture	2539	USD
	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	0	USD
	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	5000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	76	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25000	USD
CY2020Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4185000	shares
CY2020Q3	xeri	Proceeds From Warrants Exercises ProceedsFromWarrantsExercises	125550	USD
CY2020Q3	xeri	Common Stock Issued For Prior Period Conversions Principal And Interest CommonStockIssuedForPriorPeriodConversionsPrincipalAndInterest	10598544	shares
CY2020Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	167550	USD
CY2020Q3	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	4985	USD
CY2021Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	123600	shares
CY2021Q4	xeri	Proceeds From Warrants Exercises ProceedsFromWarrantsExercises	3000	USD
CY2020Q3	xeri	Common Stock Shares Issued In Exchange For Services CommonStockSharesIssuedInExchangeForServices	250000	shares
CY2020Q3	xeri	Common Stock Shares Issued In Exchange For Services Value CommonStockSharesIssuedInExchangeForServicesValue	46400	USD
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	250000	USD
CY2021Q4	xeri	Fair Value Of Stock Option FairValueOfStockOption	3543787	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1887545	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	19000000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2375000	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y6M18D
CY2021Q4	us-gaap	Cash Cash	2110549	USD
CY2021Q4	xeri	Working Capital Deficit WorkingCapitalDeficit	1305399	USD
CY2021Q2	xeri	Working Capital Deficit WorkingCapitalDeficit	677257	USD
	us-gaap	Profit Loss ProfitLoss	-9974398	USD
	us-gaap	Profit Loss ProfitLoss	-1520421	USD

Files In Submission

Name	View Source	Status
0001477932-22-000865-index-headers.html	Edgar Link	pending
0001477932-22-000865-index.html	Edgar Link	pending
0001477932-22-000865.txt	Edgar Link	pending
0001477932-22-000865-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xeri-20211231.xsd	Edgar Link	pending
xeri-20211231_cal.xml	Edgar Link	unprocessable
xeri-20211231_def.xml	Edgar Link	unprocessable
xeri-20211231_lab.xml	Edgar Link	unprocessable
xeri-20211231_pre.xml	Edgar Link	unprocessable
xeri_10q.htm	Edgar Link	pending
xeri_10q_htm.xml	Edgar Link	completed
xeri_ex311.htm	Edgar Link	pending
xeri_ex312.htm	Edgar Link	pending
xeri_ex321.htm	Edgar Link	pending
xeri_ex322.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERI
XERIANT, INC. Stock $xeri

2022 Q1 Form 10-Q Financial Statement

#000147793222000865 Filed on February 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI XERIANT, INC. Stock $xeri

2022 Q1 Form 10-Q Financial Statement

#000147793222000865 Filed on February 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI
XERIANT, INC. Stock $xeri